This inventor holds 5 USPTO granted patents and 9 published patent applications, plus 2 CIPO patents and 2 EPO patents. Top assignees: Novo Nordisk A/s, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Yale University. Active years: 2021-2026.
Company Filing History:
4 out of 1,801 
3 out of 3,690 
1 out of 1,363 
Years Active: 2021-2026
Title: Innovations and Contributions of Madhav N Devalaraja
Introduction
Madhav N Devalaraja is a notable inventor based in Acton, MA (US). He has made significant contributions to the field of medical research, particularly in the treatment of heart failure and hypertriglyceridemia. With a total of 5 patents to his name, his work has had a meaningful impact on healthcare.
Latest Patents
Among his latest patents is a treatment for diuretic-resistant heart failure patients who possess at least one copy of the TMPRSS6 rs855791 allele. Additionally, he has developed apolipoprotein C-II (apoC-II) mimetic peptides, which provide methods for treating hypertriglyceridemia in patients using an effective amount of these peptides.
Career Highlights
Madhav has worked with prominent organizations such as Novo Nordisk A/S and the United States of America, as represented by the Secretary, Department of Health and Human Services. His experience in these institutions has allowed him to contribute to significant advancements in medical treatments.
Collaborations
Madhav has collaborated with esteemed colleagues, including Chih-Hung Lo and Rahul Kakkar. Their joint efforts have furthered research and innovation in their respective fields.
Conclusion
Madhav N Devalaraja's contributions to medical research and innovation are commendable. His patents and collaborations reflect his dedication to improving healthcare outcomes.